RORγt is regarded as the key transcription factor controlling the differentiation of naive CD4+ T cells into Th17 lineage, and currently it has become an important therapeutic target for Th17 mediated autoimmune diseases and inflammatory disorders [26, 52–54]. This evidence concerns the gene CD4 and autoimmune disease.